These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6416718)

  • 1. Sustained gonadal suppression in fertile women with the LHRH agonist buserelin.
    Hardt W; Schmidt-Gollwitzer M
    Clin Endocrinol (Oxf); 1983 Nov; 19(5):613-7. PubMed ID: 6416718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns.
    Kuhl H; Jung C; Taubert HD
    Clin Endocrinol (Oxf); 1984 Aug; 21(2):179-88. PubMed ID: 6432376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.
    Brogden RN; Buckley MM; Ward A
    Drugs; 1990 Mar; 39(3):399-437. PubMed ID: 2109679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis.
    Lemay A; Maheux R; Faure N; Jean C; Fazekas AT
    Fertil Steril; 1984 Jun; 41(6):863-71. PubMed ID: 6427019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
    Carlström K; Lunell NO; Zador G
    Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endometrial patterns in women on chronic luteinizing hormone-releasing hormone agonist treatment for contraception.
    Bergquist C; Nillius SJ; Wide L; Lindgren A
    Fertil Steril; 1981 Sep; 36(3):339-42. PubMed ID: 6793403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progress in the contraceptive use of the LH-RH agonist buserelin: intermittent medication with gestagen-induced withdrawal bleeding].
    Hardt W; Schmidt-Gollwitzer K; Nevinny-Stickel J; Schmidt-Gollwitzer M
    Geburtshilfe Frauenheilkd; 1982 Dec; 42(12):874-7. PubMed ID: 6819180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer.
    Klijn JG; de Jong FH
    Lancet; 1982 May; 1(8283):1213-6. PubMed ID: 6122975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of luteinizing hormone and gonadal steroid responses to single intranasal administration of an LHRH agonist (Hoe-766) in young normal adult men.
    Faure N; Labrie F; Belanger A; Lemay A; Raynaud JP; Von der Ohe M; Fazekas AT
    J Endocrinol Invest; 1982; 5(6):355-60. PubMed ID: 6820372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic treatment with a LH-RH-agonist: a new contraceptive method?
    Schmidt-Gollwitzer M; Hardt W; Schmidt-Gollwitzer K; Nevinny-Stickel J
    Acta Eur Fertil; 1981 Sep; 12(3):275-6. PubMed ID: 6803498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
    Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
    Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N; Bastide A
    Fertil Steril; 1987 Jan; 47(1):60-6. PubMed ID: 2947818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist.
    Lemay A; Quesnel G
    Fertil Steril; 1982 Sep; 38(3):376-9. PubMed ID: 6214431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteinizing hormone releasing hormone agonist for contraception in breast feeding women.
    Fraser HM; Dewart PJ; Smith SK; Cowen GM; Sandow J; McNeilly AS
    J Clin Endocrinol Metab; 1989 Nov; 69(5):996-1002. PubMed ID: 2507572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic effects of the stimulatory luteinizing hormone-releasing hormone analogue D-Ser (TBU) 6-EA 10-LRH on the gonadotrophin and gonadal steroid secretion in women with amenorrhoea.
    Skarin G; Nillius SJ; Wide L
    Ups J Med Sci; 1980; 85(2):103-12. PubMed ID: 6787767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endometrial histology during intermittent intranasal luteinizing hormone-releasing hormone (LH-RH) agonist sequentially combined with an oral progestogen as an antiovulatory contraceptive approach.
    Lemay A; Jean C; Faure N
    Fertil Steril; 1987 Nov; 48(5):775-82. PubMed ID: 2959569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pituitary and ovarian suppression rate after high dosage of gonadotropin-releasing hormone agonist.
    Bider D; Ben-Rafael Z; Shalev J; Goldenberg M; Mashiach S; Blankstein J
    Fertil Steril; 1989 Apr; 51(4):578-81. PubMed ID: 2494078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal relationships between ovulation and defined changes in the concentration of plasma estradiol-17 beta, luteinizing hormone, follicle-stimulating hormone, and progesterone. I. Probit analysis. World Health Organization, Task Force on Methods for the Determination of the Fertile Period, Special Programme of Research, Development and Research Training in Human Reproduction.
    Am J Obstet Gynecol; 1980 Oct; 138(4):383-90. PubMed ID: 6775535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.